SCHEMBL4559299

SCHEMBL4559299

CONC(=O)C(OC)(c1ccccc1)N1CCNCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 4/20 0.39
KMT2A Q03164 3/20 0.37
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 2/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
POLB P06746 1/20 0.37
KCNN4 O15554 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
CES1 P23141 1/20 0.34
USP2 O75604 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4558785 0.85 KMT2A (0.40) OPRD1KMT2AALDH1A1MEN1MAPT
SCHEMBL4186774 0.72 SMN1; SMN2 (0.46) OPRD1ALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL4559888 0.71 CYP2B6 (0.47) KMT2AALDH1A1MEN1MAPTKCNN4
SCHEMBL4559293 0.70 CES1 (0.45) OPRD1KMT2AALDH1A1MEN1MAPT
SCHEMBL1080004 0.70 SIGMAR1 (0.41) OPRD1KMT2AALDH1A1MEN1MAPT
SCHEMBL4125494 0.69 CYP2B6 (0.41) OPRD1KMT2AALDH1A1MEN1MAPT
SCHEMBL6904745 0.69 CES1 (0.58) KMT2AALDH1A1MEN1MAPTKCNN4
SCHEMBL28615437 0.68 KCNN4 (0.62) KMT2AMAPTKCNN4KDM4ECES1
SCHEMBL18284663 0.68 SIGMAR1 (0.45) OPRD1KMT2AALDH1A1MEN1MAPT
SCHEMBL3624304 0.68 KMT2A (0.38) OPRD1KMT2AALDH1A1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501407-B2 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2009-03-10 US disclosed
US-6916804-B2 Pyrimidine A2b selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2005-07-12 US disclosed
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use ADORA2B, ADORA2A, ADORA3 OPRD1 302/4885KMT2A 2079/4885ALDH1A1 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.